Top

Current Cardiology Reports

Published in:

Open Access 01-04-2017 | Management of Acute Coronary Syndromes (AS Jaffe, Section Editor)

Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins

Authors: K. M. Eggers, B. Lindahl

Published in: Current Cardiology Reports | Issue 4/2017

Abstract

Purpose of Review

Cardiac troponin (cTn) plays an essential role for assessment of outcome in acute coronary syndrome (ACS). However, the prognostic value of cTn is not absolute. In this mini-review, we summarize the evidence on the utility of established biomarkers of left-ventricular dysfunction, hemodynamic stress, inflammation, and renal dysfunction for risk prediction beyond cTn in ACS.

Recent Findings

Only few biomarkers consistently demonstrate additive prognostic value to cTn levels. The B-type natriuretic peptides (NPs) and growth-differentiation factor-15 (GDF-15) are most promising in this regard. However, there are uncertainties regarding the role of these biomarkers for guidance of treatment decisions, and their prognostic increment to cTn levels measured with high-sensitivity assays is largely unknown.

Summary

The NPs and GDF-15 provide the strongest prognostic increment to cTn levels in ACS. However, the role of these biomarkers for clinical decision-making in contemporary settings has still to be defined.

White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011;57:2406–8. doi:10.1016/j.jacc.2011.01.029. Erratum in J Am Coll Cardiol 2011;58:2356.CrossRefPubMed

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–98. doi:10.1016/j.jacc.2012.08.001.CrossRefPubMed

Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. FRISC II (Fast Revascularization during InStability in CAD) Investigators. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol. 2001;38:979–86.CrossRefPubMed

Hallén J. Troponin for the estimation of infarct size: what have we learned? Cardiology. 2012;121:204–12. doi:10.1159/000337113.CrossRefPubMed

Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405–12.CrossRefPubMed

James SK, Lindbäck J, Tilly J, Siegbahn A, Venge P, Armstrong P, et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol. 2006;48:1146–54. doi:10.1016/j.jacc.2006.05.056.CrossRefPubMed

Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–68. doi:10.1016/j.jacc.2007.09.021.CrossRefPubMed

Talwar S, Squire IB, Downie PF, Mccullough AM, Campton MC, Davies JE, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J. 2000;21:1514–21. doi:10.1053/euhj.1999.2045.CrossRefPubMed

Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003;41:1264–72. Erratum in: J Am Coll Cardiol 2003;41:1852.CrossRefPubMed

10.

Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003;42:1909–16.CrossRefPubMed

11.

Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335–9. doi:10.1016/j.jacc.2004.04.033.CrossRefPubMed

12.

Björklund E, Jernberg T, Johanson P, Venge P, Dellborg M, Wallentin L, et al. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart. 2006;92:735–40. doi:10.1136/hrt.2005.072975.CrossRefPubMed

13.

Mayr A, Mair J, Schocke M, Klug G, Pedarnig K, Haubner BJ, et al. Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function. Int J Cardiol. 2011;147:118–23. doi:10.1016/j.ijcard.2009.09.537.CrossRefPubMed

14.

• Lindahl B, Lindbäck J, Jernberg T, Johnston N, Stridsberg M, Venge P, et al. Serial analyses of N-terminal pro-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol. 2005;45:533–41. doi:10.1016/j.jacc.2004.10.057. One of the few studies investigating the prognostic implications of changes in NT-proBNP levels after NSTE-ACS and the optimal timing of measurements.CrossRefPubMed

15.

•• James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275–81. doi:10.1161/01.CIR.0000079170.10579.DC. A large analysis that confirmed the prognostic value of NT-proBNP as a mortality predictor independent of cTnT, CRP or estimates of renal dysfunction. CrossRefPubMed

16.

Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005;294:2866–71. doi:10.1001/jama.294.22.2866.CrossRefPubMed

17.

Khan SQ, Narayan H, Ng KH, Dhillon OS, Kelly D, Quinn P, et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci (Lond). 2009;117:31–9. doi:10.1042/CS20080419.CrossRef

18.

•• Widera C, Pencina MJ, Bobadilla M, Reimann I, Guba-Quint A, Marquardt I, et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem. 2013;59:1497–505. doi:10.1373/clinchem.2013.206185. One of the few analyses investigating the incremental value of multiple biomarkers to an established risk prediction tool in NSTE-ACS. CrossRefPubMed

19.

Sadanandan S, Cannon CP, Chekuri K, Murphy SA, Dibattiste PM, Morrow DA, et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44:564–8. doi:10.1016/j.jacc.2004.03.072.CrossRefPubMed

20.

Squire IB, Ørn S, Ng LL, Manhenke C, Shipley L, Aarsland T, et al. Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. J Card Fail. 2005;11:492–7. doi:10.1016/j.cardfail.2005.05.004.CrossRefPubMed

21.

•• Dong SY, Dong MS, Chen ZH, Sun J, Yang X, Zeng Q. Dynamic use of B-type natriuretic peptide-guided acute coronary syndrome therapy. Am J Med Sci. 2014;348:283–7. doi:10.1097/MAJ.0000000000000245. This meta-analysis confirmed the prognostic benefit of early coronary revascularization in ACS patients with higher NP levels. CrossRefPubMed

22.

Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014;129:293–303. doi:10.1161/CIRCULATIONAHA.113.004420.CrossRefPubMed

23.

Squire I, Quinn P, Narayan H, Khan S, Dhillon O, Ng K, et al. Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP. Heart. 2010;96:831–7. doi:10.1136/hrt.2009.184614.CrossRefPubMed

24.

Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010;31:1993–2005. doi:10.1093/eurheartj/ehq190.CrossRefPubMed

25.

Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010;55:1189–96. doi:10.1016/j.jacc.2009.09.068.CrossRefPubMed

26.

Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16 Suppl 1:S37–44. doi:10.1111/j.1751-7133.2010.00177.x.CrossRefPubMed

27.

Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54:60–8. doi:10.1016/j.jacc.2009.01.076.CrossRefPubMed

28.

Stallone F, Twerenbold R, Wildi K, Reichlin T, Rubini Gimenez M, Haaf P, et al. Prevalence, characteristics and outcome of non-cardiac chest pain and elevated copeptin levels. Heart. 2014;100:1708–14. doi:10.1136/heartjnl-2014-305583.CrossRefPubMed

29.

Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail. 2008;14:739–45. doi:10.1016/j.cardfail.2008.07.231.CrossRefPubMed

30.

Khan SQ, Dhillon OS, O’Brien RJ, Struck J, Quinn PA, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115:2103–10. doi:10.1161/CIRCULATIONAHA.106.685503.CrossRefPubMed

31.

Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009;30:1187–94. doi:10.1093/eurheartj/ehp098.CrossRefPubMed

32.

•• O’Malley RG, Bonaca MP, Scirica BM, Murphy SA, Jarolim P, Sabatine MS, et al. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol. 2014;63:1644–53. doi:10.1016/j.jacc.2013.12.034. Erratum in: J Am Coll Cardiol 2014;63:2642. This large analysis confirmed that biomarkers reflective of hemodynamic stress including copeptin add to the prognostic value obtained from cTnT in NSTE-ACS.

33.

Balmelli C, Meune C, Twerenbold R, Reichlin T, Rieder S, Drexler B, et al. Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men. Am Heart J. 2013;166:30–7. doi:10.1016/j.ahj.2013.03.014.CrossRefPubMed

34.

Pepys MB. C-reactive protein fifty years on. Lancet. 1981;1:653–7.CrossRefPubMed

35.

He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart. 2010;96:339–46. doi:10.1136/hrt.2009.174912.CrossRefPubMed

36.

de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982;47:239–43.CrossRefPubMedPubMedCentral

37.

Smith SJ, Bos G, Esseveld MR, Van Eijk HG, Gerbrandy J. Acute-phase proteins from the liver and enzymes from myocardial infarction; a quantitative relationship. Clin Chim Acta. 1977;81:75–85.CrossRefPubMed

38.

Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. doi:10.1136/bmj.d548.CrossRefPubMed

39.

Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417–24.CrossRefPubMed

40.

• James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol. 2003;41:916–24. This large analysis demonstrated that CRP levels add prognostic increment to cTnT regarding the prediction of mortality in NSTE-ACS whereas there was no added value regarding the prediction of recurrent ischemic events. CrossRefPubMed

41.

Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998;31:1460–5.CrossRefPubMed

42.

Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139–47. doi:10.1056/NEJM200010193431602.CrossRefPubMed

43.

Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, Verret B, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol. 2008;51:2339–46. doi:10.1016/j.jacc.2008.03.019.CrossRefPubMed

44.

Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JL, Braunwald E, et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011;32:697–705. doi:10.1093/eurheartj/ehq468.CrossRefPubMed

45.

Biasucci LM, Koenig W, Mair J, Mueller C, Plebani M, Lindahl B, et al. How to use C-reactive protein in acute coronary care. Eur Heart J. 2013;34:3687–90. doi:10.1093/eurheartj/eht435.CrossRefPubMed

46.

Weinberg E, Shimpo M, De Keulenaer G, MacGillivray C, Tominaga S, Solomon S, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–6.CrossRefPubMedPubMedCentral

47.

Januzzi Jr JL. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res. 2013;6:493–500. doi:10.1007/s12265-013-9459-y.CrossRefPubMed

48.

Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012;58:257–66. doi:10.1373/clinchem.2011.173369.CrossRefPubMed

49.

Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. Am J Cardiol. 2015;115(7 Suppl):48B–58. doi:10.1016/j.amjcard.2015.01.041.CrossRefPubMed

50.

Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail. 2012;18:304–10. doi:10.1016/j.cardfail.2012.01.008.CrossRefPubMed

51.

Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936–44. doi:10.1161/CIRCULATIONAHA.107.728022.CrossRefPubMedPubMedCentral

52.

Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186–90. doi:10.1161/01.CIR.0000127958.21003.5A.CrossRefPubMed

53.

Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB, et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol. 2013;167:2182–8. doi:10.1016/j.ijcard.2012.05.073.CrossRefPubMed

54.

• O’Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW. Multimarker risk stratification in patients with acute myocardial infarction. J Am Heart Assoc. 2016;5:e002586. doi:10.1161/JAHA.115.002586. In this head-to-head analysis of 11 biomarkers reflective of different pathobiological pathways, ST2 together with myeloperoxidase and cTnT were the only biomarkers that independently predicted adverse outcome in STEMI.CrossRefPubMedPubMedCentral

55.

Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243–50. doi:10.1016/j.jacc.2009.08.047.CrossRefPubMed

56.

Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013;24:373–84. doi:10.1016/j.cytogfr.2013.05.003.CrossRefPubMed

57.

Zhang S, Dai D, Wang X, Zhu H, Jin H, Zhao R, et al. Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 2016;16:82. doi:10.1186/s12872-016-0250-2.CrossRefPubMedPubMedCentral

58.

•• Hagstrom E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016;37:1325–33. doi:10.1093/eurheartj/ehv491. This study confirmed the strong value of GDF-15 as a predictor of global risk independent of hs-cTnT levels. CrossRefPubMed

59.

Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011;31:203–10. doi:10.1161/ATVBAHA.CrossRefPubMed

60.

Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome. Circulation. 2007;116:1540–8. doi:10.1161/CIRCULATIONAHA.107.697714.CrossRefPubMed

61.

Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E. Biomarkers and coronary lesions predict outcomes after revascularization in non-ST-elevation acute coronary syndrome. Clin Chem. 2016. doi:10.1373/clinchem.2016.261271.PubMed

62.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed

63.

Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A.

64.

Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, Harrington RA, et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991–6. doi:10.1016/j.jacc.2007.11.045.CrossRefPubMed

65.

Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, Stenestrand U, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med. 2010;268(1):40–9. doi:10.1111/j.1365-2796.2009.02204.x.PubMed

66.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. Erratum in: Ann Intern Med 2011;155:408.CrossRefPubMedPubMedCentral

67.

•• Åkerblom A, Wallentin L, Larsson A, Siegbahn A, Becker RC, Budaj A, et al. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clin Chem. 2013;59:1369–75. doi:10.1373/clinchem.2012.200709. The so far largest study investigating the prognostic value of estimates of renal dysfunction in ACS, including cystatin C.CrossRefPubMed

68.

Mueller C, Neumann FJ, Perruchoud AP, Buettner HJ. Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. Heart. 2004;90:902–7. doi:10.1136/hrt.2003.021741.CrossRefPubMedPubMedCentral

69.

Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol. 2002;40:2065–71.CrossRefPubMed

70.

Parikh RH, Seliger SL, deFilippi CR. Use and interpretation of high sensitivity cardiac troponins in patients with chronic kidney disease with and without acute myocardial infarction. Clin Biochem. 2015;48:247–53. doi:10.1016/j.clinbiochem.2015.01.004.CrossRefPubMed

71.

Diris JH, Hackeng CM, Kooman JP, Pinto YM, Hermens WT, van Dieijen-Visser MP. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation. 2004;109:23–5. doi:10.1161/01.CIR.0000109483.45211.8F.CrossRefPubMed

72.

Melloni C, Alexander KP, Milford-Beland S, Newby LK, Szczech LA, Pollack CV, et al. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. Clin Cardiol. 2008;31:125–9. doi:10.1002/clc.20210.CrossRefPubMed

73.

Newman DJ, Cystatin C. Ann Clin Biochem. 2002;39:89–104.CrossRefPubMed

74.

Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699–707.PubMed

75.

Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359–66. doi:10.1161/01.ATV.0000134530.27208.41.CrossRefPubMed

76.

Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342–8. doi:10.1161/01.CIR.0000145166.44942.E0.CrossRefPubMed

77.

Kilic T, Oner G, Ural E, Yumuk Z, Sahin T, Bildirici U, et al. Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis. 2009;207:552–8. doi:10.1016/j.atherosclerosis.2009.05.015.CrossRefPubMed

78.

García Acuña JM, González-Babarro E, Grigorian Shamagian L, Peña-Gil C, Vidal Pérez R, López-Lago AM, et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol. 2009;62:510–9.CrossRefPubMed

79.

Van Eyk JE. Overview: the maturing of proteomics in cardiovascular research. Circ Res. 2011;108:490–8. doi:10.1161/CIRCRESAHA.110.226894.CrossRefPubMedPubMedCentral

80.

Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. Proteomics. 2012;12:722–35. doi:10.1002/pmic.201100346.CrossRefPubMedPubMedCentral

81.

Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016;111:322–37. doi:10.1093/cvr/cvw174.CrossRefPubMedPubMedCentral

82.

Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37:1582–90. doi:10.1093/eurheartj/ehw054.CrossRefPubMedPubMedCentral

83.

Lindholm D, Lindback J, James SK, Becker RC, Himmelmann A, Siegbahn A, et al. Biomarker-based prediction model for recurrent ischemic events in revascularised patients with acute coronary syndromes. Eur Heart J. 2015;36((Abstract Supplement)):10–1.

Title: Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins
Authors: K. M. Eggers
B. Lindahl
Publication date: 01-04-2017
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 4/2017
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-017-0840-3

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2017

Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models

Coronary Stents in Diabetic Patients: State of the Knowledge

State-of-the-Art: a Review of Cardiovascular Effects of Testosterone Replacement Therapy in Adult Males

Cardio-oncology: the Nuclear Option

Recent Advances and Clinical Applications of PET Cardiac Autonomic Nervous System Imaging

Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page